SCHEMBL23833422

SCHEMBL23833422

COc1ncc(NC(=O)c2cccc(-c3ccnn3C)c2)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 1/20 0.42
HTR2A P28223 5/20 0.41
HTR2C P28335 2/20 0.41
BRAF P15056 7/20 0.41
RAF1 P04049 5/20 0.41
KCNH2 Q12809 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
ABL1 P00519 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
LRRK2 Q5S007 1/20 0.39
DYRK3 O43781 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758282 0.86 HTR2A (0.48) CBLBHTR2AHTR2CKCNH2MEN1
SCHEMBL23840584 0.85 BLK (0.47) MEN1KMT2AKEAP1NFE2L2ABL1
SCHEMBL23840544 0.85 ALDH1A1 (0.47) MEN1KMT2APIK3C3NTRK1
SCHEMBL25483827 0.83 KAT6A (0.45) BRAFRAF1MEN1KMT2APIK3C3
SCHEMBL23833458 0.82 MAPT (0.44) HTR2AHTR2CBRAFRAF1MEN1
SCHEMBL30151027 0.82 SMN1; SMN2 (0.45) KMT2AABL1PIK3C3PRKD3PRKCD
SCHEMBL23833412 0.82 SMN1; SMN2 (0.45) KMT2AABL1PIK3C3PRKD3PRKCD
SCHEMBL25490166 0.82 DHX9 (0.53) MEN1KMT2APIK3C3FGFR1
SCHEMBL23840329 0.81 KCNK3 (0.54) BRAFMEN1KMT2AKEAP1NFE2L2
SCHEMBL23840513 0.81 TSHR (0.48) BRAFMEN1KMT2APIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D CBLB 4228/4885HTR2A 3260/4885HTR2C 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.